Goense Lucas, Borggreve Alicia S, Heethuis Sophie E, van Lier Astrid Lhmw, van Hillegersberg Richard, Mook Stella, Meijer Gert J, van Rossum Peter S N, Ruurda Jelle P
1 Department of Radiation Oncology, University Medical Center Utrecht , Utrecht , Netherlands.
2 Department of Surgery, University Medical Center Utrecht , Utrecht , Netherlands.
Br J Radiol. 2018 Jun;91(1086):20170710. doi: 10.1259/bjr.20170710. Epub 2018 Mar 14.
The perceived burden of diagnostic tests by patients during the assessment of esophageal cancer warrants attention with the current increase in repeated imaging for purposes of disease monitoring during and after treatment. The purpose of this prospective study was to evaluate the experienced burden associated with repeated MRI and positron emission tomography with integrated CT (PET/CT) examinations during neoadjuvant treatment for esophageal cancer from the perspective of the patient.
In 27 patients receiving neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer MRI and PET/CT examinations were performed before nCRT, during nCRT and before surgery. The experienced burden during repeated MRI and PET/CT examinations was evaluated with a self-report questionnaire addressing discomfort, pain, anxiety and embarrassment, each measured on a 5-point Likert scale (1 = none; up to 5 = very much). In addition, a comparative assessment was used to rank MRI, PET/CT and baseline endoscopy.
All scans were performed without the occurrence of an adverse event. Few patients experienced discomfort (mean score ±SD: 1.9 ± 1.0 for MRI vs 2.0 ± 1.0 for PET/CT, p = 0.586), pain (1.1 ± 0.4 for MRI vs 1.3 ± 0.7 for PET/CT, p = 0.059), anxiety (1.0 ± 0.2 for MRI vs 1.0 ± 0.2 for PET/CT, p = 1.000) and embarrassment (1.0 ± 0 for MRI vs 1.0 ± 0.2 for PET/CT, p = 0.317) during both MRI and PET/CT. Patients preferred MRI over PET/CT (67% vs 22%, respectively, p = 0.023), and MRI over endoscopy (59% vs 19%, respectively, p = 0.027). In the comparison between PET/CT and endoscopy, 59% of patients preferred PET/CT and 26% preferred endoscopy (p = 0.093).
Repeated imaging with both MRI and PET/CT is generally well-tolerated for the assessment of response to treatment in esophageal cancer patients. Shorter acquisition times and altered body positioning during scanning will likely improve patient experience. Advances in knowledge: This paper demonstrates that MRI and PET/CT are generally well-tolerated imaging procedures for the assessment of response to treatment in esophageal cancer patients. When asked to rank different tests, patients preferred MRI over PET/CT and endoscopy.
在食管癌评估过程中,患者对诊断检查的感知负担值得关注,因为目前为了治疗期间及治疗后的疾病监测而增加了重复成像检查。这项前瞻性研究的目的是从患者角度评估食管癌新辅助治疗期间重复进行磁共振成像(MRI)和正电子发射断层显像/X线计算机体层成像(PET/CT)检查所带来的负担。
对27例接受食管癌新辅助放化疗(nCRT)的患者,在nCRT前、nCRT期间及手术前进行MRI和PET/CT检查。采用一份自我报告问卷评估重复进行MRI和PET/CT检查期间的负担,问卷涉及不适、疼痛、焦虑和尴尬情况,每项均采用5级李克特量表进行测量(1 = 无;最高5 = 非常严重)。此外,采用比较评估法对MRI、PET/CT和基线内镜检查进行排序。
所有扫描均未发生不良事件。很少有患者在MRI和PET/CT检查期间出现不适(MRI的平均得分±标准差:1.9±1.0,PET/CT为2.0±1.0,p = 0.586)、疼痛(MRI为1.1±0.4,PET/CT为1.3±0.7,p = 0.059)、焦虑(MRI为1.0±0.2,PET/CT为1.0±0.2,p = 1.000)和尴尬(MRI为1.0±0,PET/CT为1.0±0.2,p = 0.317)。患者更喜欢MRI而非PET/CT(分别为67%对22%,p = 0.023),更喜欢MRI而非内镜检查(分别为59%对19%,p = 0.027)。在PET/CT和内镜检查的比较中,59%的患者更喜欢PET/CT,26%的患者更喜欢内镜检查(p = 0.093)。
对于评估食管癌患者的治疗反应,重复进行MRI和PET/CT成像通常耐受性良好。缩短采集时间和在扫描过程中改变身体姿势可能会改善患者体验。知识进展:本文表明,MRI和PET/CT是评估食管癌患者治疗反应时通常耐受性良好的成像检查方法。当被要求对不同检查进行排序时,患者更喜欢MRI而非PET/CT和内镜检查。